Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Naldemedine for Opioid-induced Constipation
NCT01965652Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of naldemedine in opioid-induced constipation (OIC), sponsored by Shionogi & Co., Ltd.. Started Sep 2013; status: completed.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01965652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965652.